Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 4/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | HPN | P05981 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2925960 | 0.90 | AKT1 (0.42) | GRM2L3MBTL1NAMPTAKT1AAK1 | |
| SCHEMBL20770858 | 0.84 | GRM2 (0.46) | GRM2L3MBTL1NAMPTAKT1DYRK1A | |
| SCHEMBL13175635 | 0.82 | MTNR1A (0.40) | L3MBTL1AAK1TDP1KDM4E | |
| SCHEMBL7022247 | 0.80 | GRM2 (0.48) | GRM2L3MBTL1NAMPTAKT1DYRK1A | |
| SCHEMBL30445886 | 0.78 | GRM2 (0.47) | GRM2L3MBTL1NAMPTAKT1DYRK1A | |
| SCHEMBL20782643 | 0.78 | GRM2 (0.47) | GRM2L3MBTL1NAMPTAKT1DYRK1A | |
| SCHEMBL20782574 | 0.78 | ENPP3 (0.62) | GRM2L3MBTL1NAMPTAKT1DYRK1A | |
| SCHEMBL2925161 | 0.77 | GRM2 (0.40) | GRM2 | |
| SCHEMBL1723633 | 0.76 | KDM4E (0.38) | L3MBTL1AAK1TDP1KDM4E | |
| SCHEMBL1723632 | 0.76 | KDM4E (0.38) | L3MBTL1AAK1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560488-B1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-7618959-B2 | Antibacterial agents | SMITHKLINEBEECHAM CORP (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070004710-A1 | Antibacterial agents | SMITHKLINE BEECHAM CORPORATION | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004710-A1 | Antibacterial agents | NQO2, NRDC, IFNG | GRM2 4881/4885L3MBTL1 1253/4885NAMPT 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.